On the cusp of FDA approval for its NASH drug, Intercept?s CEO talks payers, pruritis, and price

It?s been a long and bumpy road, but Intercept?s NASH drug, called obeticholic acid, is finally on the cusp of a FDA approval.?

Click to view original post